Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Higher Naloxone Doses Narrowly Favored By FDA Panel

Executive Summary

Divided advisory committee concludes the current naloxone approval standard is inadequate due in part to increase in overdoses from powerful synthetic opioids, but doesn't offer FDA a clear alternative.


Related Content

Amphastar's Naloxone Nasal Spray Delayed; User Human Factors Study Among FDA Concerns
Unapproved Petitioner: Clinical-Stage Firm Wants FDA Scrutiny Of Naloxone Formulations
FDA’s Opioid Crisis Response: More Pressure For Treatment Drugs
Naloxone Efficacy Standard Changes Could Impact Amphastar's Pending NDA
Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation
Recent And Upcoming FDA Advisory Committees
FDA’s Naloxone Product Approval Standards May See Changes


Related Companies